全文获取类型
收费全文 | 61182篇 |
免费 | 5192篇 |
国内免费 | 2040篇 |
专业分类
耳鼻咽喉 | 658篇 |
儿科学 | 1153篇 |
妇产科学 | 655篇 |
基础医学 | 12558篇 |
口腔科学 | 1037篇 |
临床医学 | 3923篇 |
内科学 | 9528篇 |
皮肤病学 | 1323篇 |
神经病学 | 4398篇 |
特种医学 | 959篇 |
外国民族医学 | 17篇 |
外科学 | 4569篇 |
综合类 | 7149篇 |
现状与发展 | 9篇 |
预防医学 | 2668篇 |
眼科学 | 678篇 |
药学 | 9772篇 |
4篇 | |
中国医学 | 2367篇 |
肿瘤学 | 4989篇 |
出版年
2024年 | 159篇 |
2023年 | 1189篇 |
2022年 | 2473篇 |
2021年 | 2556篇 |
2020年 | 2000篇 |
2019年 | 2367篇 |
2018年 | 2450篇 |
2017年 | 2362篇 |
2016年 | 2075篇 |
2015年 | 2412篇 |
2014年 | 3472篇 |
2013年 | 4099篇 |
2012年 | 3530篇 |
2011年 | 4194篇 |
2010年 | 3301篇 |
2009年 | 3278篇 |
2008年 | 3009篇 |
2007年 | 2744篇 |
2006年 | 2456篇 |
2005年 | 2042篇 |
2004年 | 1918篇 |
2003年 | 1604篇 |
2002年 | 1239篇 |
2001年 | 948篇 |
2000年 | 930篇 |
1999年 | 794篇 |
1998年 | 769篇 |
1997年 | 734篇 |
1996年 | 631篇 |
1995年 | 661篇 |
1994年 | 575篇 |
1993年 | 482篇 |
1992年 | 415篇 |
1991年 | 389篇 |
1990年 | 354篇 |
1989年 | 287篇 |
1988年 | 238篇 |
1987年 | 229篇 |
1986年 | 240篇 |
1985年 | 414篇 |
1984年 | 482篇 |
1983年 | 311篇 |
1982年 | 337篇 |
1981年 | 263篇 |
1980年 | 234篇 |
1979年 | 181篇 |
1978年 | 115篇 |
1977年 | 117篇 |
1976年 | 130篇 |
1975年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
目的探讨单纯 Ilizarov 环形外固定技术治疗合并骨筋膜室综合征的胫骨平台骨折的疗效。方法2013 年 9 月—2017 年 3 月,收治 30 例合并骨筋膜室综合征的胫骨平台骨折患者,采用单纯 Ilizarov 环形外固定技术治疗。男 23 例,女 7 例;年龄 23~43 岁,平均 34.4 岁。致伤原因:交通事故伤 12 例,高处坠落伤 4 例,摔伤 8 例,重物砸伤 6 例。受伤至入院时间 1~12 h,平均 4.8 h。骨折 Schatzker 分型:Ⅱ型 1 例、Ⅲ型 3 例、Ⅳ型 10 例、Ⅴ型 7 例、Ⅵ型 9 例。30 例均因骨筋膜室综合征行切开减压;切开减压至手术时间为 10~15 d,平均 12.5 d。治疗后采用膝关节学会评分系统(KSS)及 Ilizarov 方法研究与应用协会(ASAMI)协议评价膝关节功能。结果手术时间 110~155 min,平均 123.1 min;术中出血量 100~500 mL,平均 245 mL;术后住院时间 3~5 d,平均 3.8 d。患者均获随访,随访时间 20~24 周,平均 22.7 周。除 2 例患者出现针道感染征象外,无其他并发症发生。X 线片复查显示骨折均愈合,愈合时间 10~20 周,平均 14.6 周。末次随访时,膝关节 KSS 临床评分总分为 70~95 分,平均 87.5 分;功能评分总分为 70~90 分,平均 79.0 分。参照 ASAMI 协议评价获优 24 例、良 3 例、可 2 例、差 1 例。结论对于合并骨筋膜室综合征的胫骨平台骨折,单纯 Ilizarov 环形外固定技术治疗后患者关节功能可以基本恢复且并发症少,是一项相对安全、有效的治疗方法。 相似文献
12.
13.
《Journal of vascular surgery》2020,71(6):1921-1929
ObjectiveIdentifying biomarkers for abdominal aortic aneurysms (AAA) could prove beneficial in prognosis of AAA and thus the selection for treatment. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein that is highly expressed in aorta. MFAP4 is involved in several tissue remodeling-related diseases. We aimed to investigate the potential role of plasma MFAP4 (pMFAP4) as a biomarker of AAA.MethodsPlasma samples and data were obtained for 504 male AAA patients and 188 controls in the Viborg Vascular (VIVA) screening trial. The pMFAP4 levels were measured by Alphalisa. The Mann-Whitney U test assessed differences in pMFAP4 levels between the presence and absence of different exposures of interest. The correlation between pMFAP4 and aorta growth rate were investigated through spearman's correlation analysis. Immunohistochemistry and multiple logistic regression adjusted for potential confounders assessed the association between pMFAP4 and AAA. Multiple linear regression assessed the correlation between pMFAP4 and aorta growth rate. Cox regression and competing risk regression were used to investigate the correlation between AAA patients with upper tertile pMFAP4 and the risk of undergoing later surgical repair.ResultsA significant negative correlation between pMFAP4 and aorta growth rate was observed using spearman's correlation analysis (ρ = −0.14; P = .0074). However, this finding did not reach significance when applying multiple linear regression. A tendency of decreased pMFAP4 was observed in AAA using immunohistochemistry. Competing risk regression adjusted for potential confounders indicated that patients with upper tertile pMFAP4 had a hazard ratio of 0.51 (P = .001) for risk of undergoing later surgical repair.ConclusionsHigh levels of pMFAP4 are associated with a decreased likelihood of receiving surgical repair in AAA. This observation warrants confirmation in an independent cohort. 相似文献
14.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
15.
16.
17.
Niya Narayanan Dukhabandhu Naik Jayaprakash Sahoo Sadishkumar Kamalanathan 《World Journal of Virology》2022,11(6):399-410
Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality and complications in patients with diabetes mellitus. Achieving good glycemic control is very important in diabetic patients to reduce complications and mortality due to COVID-19. Recent studies have shown the mortality benefit and anti-inflammatory effects of Dipeptidyl-peptidase-4 inhibitors (DPP-4i) in diabetic patients with COVID-19. DPP-4i may have a beneficial role in halting the severity of infection primarily by three routes, namely viral entry inhibition, anti-inflammatory and anti-fibrotic effects and glycemic control. This has raised the pro-mising hypothesis that DPP-4i might be an optimal strategy for treating COVID-19 in patients with diabetes. This review aims to summarise the possible therapeutic non-glycemic effects of DPP-4i in diabetic patients diagnosed with COVID-19 in the light of available evidence. 相似文献
18.
19.
《Clinical genitourinary cancer》2022,20(3):e217-e226
Background: Intraductal carcinoma and cribriform (IDC/C) tumor features are well-established prognosticators of biochemical recurrence (BCR), metastasis, and prostate cancer (PCa)-specific mortality. However, approximately 70% of PCa patients undergoing a radical prostatectomy are IDC/C negative, yet up-to 20% of these patients progress and experience BCR. Thus, tumor histopathologic characteristics such as IDC/C alone are limited in their ability to predict disease progression. Conversely, several nomograms such as Cancer of the Prostate Risk Assessment-Surgery (CAPRA-S) have been developed to aid in the prognostication of BCR, but not yet widely applied in clinical settings. Materials and methods: In this study, we assessed the combined prognostic utility of IDC/C, and CAPRA-S for BCR in 3 PCa patient cohorts. Results: CAPRA-S+IDC/C improved the predictive accuracy of BCR in all 3 cohorts (P < .001). Specifically, among IDC/C negative cases, CAPRA-S improved the prognostication of BCR in low-risk (Cohort 1; P < .001, Cohort 2; P < .001, Cohort 3; P = .003), intermediate (Cohort 1; P < .001, Cohort 2; P = .006, Cohort 3; P = .03) and high-risk (Cohort 1-3; P < .001) patients. Conversely, IDC/C improved the prognostication of BCR among CAPRA-S low-risk (Cohorts 1; P < .001 and Cohort 3; P = .003) patients. Conclusion: Our results suggest the investigation of histopathological IDC/C features in CAPRA-S low-risk patients and conversely, nomogram CAPRA-S among IDC/C negative patients improves the identification of patients likely to experience BCR, which would otherwise be missed through current assessment regimens. These patients can be offered more intensive monitoring and adjuvant therapies upfront to circumvent the development of recurrent cancer or overtreatment at the time of surgery. 相似文献
20.
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding Cassette Subfamily C Member 4 (ABCC4) polymorphisms on hematotoxicity in pediatric patients who received a standard low starting dose of 6-MP. One hundred and sixty-nine pediatric patients were enrolled and their genotypes were determined. Patients who carried NUDT1513 and NUDT1512 genotypes were at a 10–15 fold higher risk of severe neutropenia than those of the wild-type during the early months of the maintenance phase. Risk of neutropenia was not significantly increased in patients with other NUDT15 variants as well as in patients with TPMT, ITPA or ABCC4 variants. These results suggest that NUDT15 polymorphisms particularly, NUDT1513 and NUDT1512, play major roles in 6-MP-induced severe hematotoxicity even when using a standard low dosage of 6-MP and genotyping of these variants is necessary in order to obtain precise tolerance doses and avoid severe hematotoxicity in pediatric patients. 相似文献